Compare Berkshire Hathaway Inc Class B (BRK.B) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Revvity Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $509.64, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while Berkshire Hathaway Inc Class B pays none, and Revvity Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | RVTY | |
|---|---|---|
Sector | Financials | Technology |
52-Week High | $529.65 | $117.75 |
52-Week Low | $465.39 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $509.58, down 3.79% on the day, with technical indicators showing a bullish trend from moving averages and strong directional momentum (ADX). Analyst consensus is positive with 57% buy ratings and no sell recommendations. The stock is near key support at $510 and resistance at $522, indicating a critical price zone.
The outlook remains favorable given strong institutional support and bullish technicals, but risks include market volatility and Berkshire Hathaway's exposure to economic cycles. Upside potential hinges on execution across its diversified holdings, while any broad market downturn could pressure the stock.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
